Genelabs, Taiwan National Health Research Institutes and Genovate To Co-Develop New Hepatitis C Treatment
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Genelabs Technologies inked a development agreement with the Taiwan National Health Research Institutes and Genovate Biotechnology to co-develop drugs to treat hepatitis C, the company announced July 23